Support WBUR

3 Experts Have Resigned From An FDA Committee Over Alzheimer's Drug Approval

Bill Chappell

Updated June 11, 2021

Dr. Aaron Kesselheim (left), a professor at Harvard Medical School, at a documentary film screening in 2018 in Boston. He has resigned from a Food and Drug Administration advisory panel over the FDA's decision to approve an Alzheimer's drug. (AP Images for AIDS Healthcare Foundation)

This article was originally published on June 11, 2021.

Medicare Copays For New Alzheimer's Drug Could Reach $11,500 Annually
An Alzheimer's Drug May Boost Cognition In People With Fragile X Syndrome
The FDA Has Approved A New Alzheimer's Drug — Here's Why That's Controversial

Support WBUR